Prime Medicine, Inc. (PRME)
(Delayed Data from NSDQ)
$5.72 USD
+0.36 (6.72%)
Updated May 9, 2024 04:00 PM ET
After-Market: $5.72 0.00 (0.00%) 5:08 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRME 5.72 +0.36(6.72%)
Will PRME be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PRME based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRME
What Makes Prime Medicine, Inc. (PRME) a New Buy Stock
Wall Street Analysts Predict an 111.38% Upside in Prime Medicine, Inc. (PRME): Here's What You Should Know
PRME: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PRME
Prime Drink Group Announces Terms of Concurrent Financing in Connection With Proposed Acquisition of Triani Canada and Provides Update on the Transaction
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)
Prime Medicine presents preclinical data on PM359
Prime Drink Group Launches Major Financing Effort
Jefferies Issues a Buy Rating on Prime Medicine, Inc. (PRME)